Standpoint Research upgraded shares of United Therapeutics (NASDAQ:UTHR) from a hold rating to a buy rating in a research report sent to investors on Friday morning, Marketbeat reports.
Several other brokerages have also recently commented on UTHR. HC Wainwright set a $95.00 price target on shares of United Therapeutics and gave the stock a hold rating in a research report on Monday, August 13th. Wedbush set a $253.00 price objective on shares of United Therapeutics and gave the stock a buy rating in a research report on Thursday, September 27th. BidaskClub raised shares of United Therapeutics from a hold rating to a buy rating in a research report on Tuesday, September 18th. Credit Suisse Group lowered shares of United Therapeutics from a neutral rating to an underperform rating in a research report on Wednesday, August 8th. Finally, TheStreet raised shares of United Therapeutics from a c+ rating to a b rating in a research report on Thursday, August 16th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $138.86.
Shares of NASDAQ UTHR traded up $1.73 during trading on Friday, reaching $123.11. The company had a trading volume of 280,107 shares, compared to its average volume of 378,544. United Therapeutics has a 52 week low of $100.57 and a 52 week high of $152.55. The company has a market cap of $5.57 billion, a PE ratio of 11.30, a P/E/G ratio of 28.86 and a beta of 1.20. The company has a current ratio of 4.64, a quick ratio of 4.35 and a debt-to-equity ratio of 0.10.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 EPS for the quarter, topping the consensus estimate of $2.57 by $1.41. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The company had revenue of $444.50 million during the quarter, compared to analysts’ expectations of $368.63 million. During the same quarter in the previous year, the company earned $4.37 EPS. United Therapeutics’s revenue was up .0% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics will post 14.77 earnings per share for the current year.
In other United Therapeutics news, Director Christopher Causey sold 810 shares of the company’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $118.00, for a total transaction of $95,580.00. Following the sale, the director now directly owns 3,925 shares of the company’s stock, valued at $463,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard Giltner sold 3,240 shares of the company’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total transaction of $419,191.20. The disclosure for this sale can be found here. Insiders have sold 4,860 shares of company stock worth $611,161 over the last ninety days. Insiders own 8.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. BlackRock Inc. grew its stake in United Therapeutics by 2.3% during the second quarter. BlackRock Inc. now owns 5,028,058 shares of the biotechnology company’s stock worth $568,925,000 after buying an additional 115,073 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of United Therapeutics by 1.5% in the second quarter. Renaissance Technologies LLC now owns 1,556,200 shares of the biotechnology company’s stock worth $176,084,000 after acquiring an additional 22,322 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of United Therapeutics in the second quarter worth about $129,555,000. Dimensional Fund Advisors LP lifted its holdings in shares of United Therapeutics by 3.4% in the second quarter. Dimensional Fund Advisors LP now owns 990,685 shares of the biotechnology company’s stock worth $112,093,000 after acquiring an additional 32,611 shares during the last quarter. Finally, First Trust Advisors LP raised its holdings in United Therapeutics by 36.3% in the 2nd quarter. First Trust Advisors LP now owns 684,956 shares of the biotechnology company’s stock valued at $77,503,000 after buying an additional 182,409 shares during the last quarter. 95.83% of the stock is currently owned by hedge funds and other institutional investors.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More: What is a conference call?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.